<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00008450</url>
  </required_header>
  <id_info>
    <org_study_id>1227.00</org_study_id>
    <secondary_id>NCI-2010-02045</secondary_id>
    <secondary_id>1227.00</secondary_id>
    <secondary_id>P01HL036444</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00008450</nct_id>
  </id_info>
  <brief_title>Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant</brief_title>
  <official_title>Induction of Mixed Hematopoietic Chimerism in Patients With Severe Combined Immunodeficiency Disorders Using Allogeneic Bone Marrow and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies total-body irradiation followed by cyclosporine and&#xD;
      mycophenolate mofetil in treating patients with severe combined immunodeficiency (SCID)&#xD;
      undergoing donor bone marrow transplant. Giving total-body irradiation (TBI) before a donor&#xD;
      bone marrow transplant using stem cells that closely match the patient's stem cells, helps&#xD;
      stop the growth of abnormal cells. It may also stop the patient's immune system from&#xD;
      rejecting the donor's stem cells. The donated stem cells may mix with the patient's immune&#xD;
      cells and help destroy any remaining abnormal cells. Sometimes the transplanted cells from a&#xD;
      donor can also make an immune response against the body's normal cells. Giving cyclosporine&#xD;
      and mycophenolate mofetil after the transplant may stop this from happening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To safely establish partial lymphoid chimerism (1-95% donor cluster of differentiation&#xD;
      [CD]3+ cells) using a non-lethal conditioning regimen in patients with severe combined&#xD;
      immunodeficiency syndrome.&#xD;
&#xD;
      II. To define the kinetics of immune reconstitution following a non-lethal conditioning&#xD;
      regimen in patients with immunodeficiency diseases.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive cyclosporine orally (PO) or intravenously (IV) on days -3 to 100 followed by&#xD;
      a taper until day 180 and mycophenolate mofetil PO or IV on days 0-40 with a taper until day&#xD;
      96 in the absence of unacceptable toxicity. Unrelated donor recipients also undergo TBI on&#xD;
      day 0. Patients undergo bone marrow transplant on day 0.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 6 months and then yearly for&#xD;
      5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 1997</start_date>
  <completion_date type="Actual">December 26, 2018</completion_date>
  <primary_completion_date type="Actual">October 25, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mixed hematopoietic chimerism in a population of pediatric patients with immunodeficiency diseases</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>It will be established whether a non-lethal conditioning regimen can successfully induce mixed hematopoietic chimerism in a population of pediatric patients with immunodeficiency diseases, without adverse effects on mortality.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Adenosine Deaminase Deficiency</condition>
  <condition>Autosomal Recessive Disorder</condition>
  <condition>Immune System Disorder</condition>
  <condition>Purine-Nucleoside Phosphorylase Deficiency</condition>
  <condition>Severe Combined Immunodeficiency</condition>
  <condition>Severe Combined Immunodeficiency With Absence of T and B Cells</condition>
  <condition>X-Linked Severe Combined Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>Treatment (cyclosporine, mycophenolate mofetil, transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclosporine PO or IV on days -3 to 100 followed by a taper until day 180 and mycophenolate mofetil PO or IV on days 0-40 with a taper until day 96 in the absence of unacceptable toxicity. Unrelated donor recipients also undergo TBI on day 0. Patients undergo bone marrow transplant on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo allogeneic bone marrow transplant</description>
    <arm_group_label>Treatment (cyclosporine, mycophenolate mofetil, transplant)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (cyclosporine, mycophenolate mofetil, transplant)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cyclosporine, mycophenolate mofetil, transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (cyclosporine, mycophenolate mofetil, transplant)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant</description>
    <arm_group_label>Treatment (cyclosporine, mycophenolate mofetil, transplant)</arm_group_label>
    <other_name>Non-myeloablative allogeneic transplant</other_name>
    <other_name>Nonmyeloablative Stem Cell Transplantation</other_name>
    <other_name>NST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (cyclosporine, mycophenolate mofetil, transplant)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with severe combined immunodeficiency syndrome:&#xD;
&#xD;
               -  SCID with presence of B lymphocytes&#xD;
&#xD;
                    -  X-linked SCID (presence of B lymphocytes)&#xD;
&#xD;
                    -  Autosomal recessive SCID&#xD;
&#xD;
          -  Patients with severe combined immunodeficiency syndrome:&#xD;
&#xD;
               -  SCID with absence of T and B lymphocytes&#xD;
&#xD;
          -  Patients with severe combined immunodeficiency syndrome:&#xD;
&#xD;
               -  Purine metabolite deficiencies, deficiencies of the purine metabolites&#xD;
&#xD;
                    -  Adenosine deaminase (ADA) deficiency&#xD;
&#xD;
                    -  Purine nucleoside phosphorylase (PNP) deficiency&#xD;
&#xD;
          -  DONOR: Related donor who is human leukocyte antigen (HLA) genotypically identical at&#xD;
             least at one haplotype and may be genotypically or phenotypically identical for&#xD;
             serological typing for HLA-A, B, C, and at the allele level for DRB1 and DQB1; related&#xD;
             donors other than siblings must be matched at HLA-A, B, and C (at highest resolution&#xD;
             available at the time of donor selection) and at DRB1 and DQB1 by deoxyribonucleic&#xD;
             acid (DNA) typing; if more than one HLA-identical sibling is available, priority will&#xD;
             be given to the oldest normal donor&#xD;
&#xD;
          -  DONOR: Unrelated donors who are prospectively matched for HLA-A, B, C, DRB1 and DQB1&#xD;
             by DNA typing at the highest resolution routinely available at the time of donor&#xD;
             selection; only a single allele disparity will be allowed for HLA-A, B, or C as&#xD;
             defined by high resolution typing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with viral associated T cell immunodeficiency disorders, such as human&#xD;
             immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Patients with other disease or organ dysfunction that would limit survival to less&#xD;
             than 30 days&#xD;
&#xD;
          -  DONOR: Identical twin&#xD;
&#xD;
          -  DONOR: Pregnancy&#xD;
&#xD;
          -  DONOR: HIV seropositive&#xD;
&#xD;
          -  DONOR: A positive anti-donor cytotoxic cross match is absolute donor exclusion&#xD;
&#xD;
          -  DONOR: Patient and donor pairs homozygous at a mismatched allele in the graft&#xD;
             rejection vector are considered a two-HLA allele mismatch, i.e., the patient is&#xD;
             A*0201, and this type of mismatch is not allowed&#xD;
&#xD;
          -  DONOR: &lt; 6 months old, &gt; 75 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauri Burroughs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 5, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2001</study_first_posted>
  <last_update_submitted>July 26, 2019</last_update_submitted>
  <last_update_submitted_qc>July 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>X-Linked Combined Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

